Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.57 |
| ▸ | CDC7 | O00311 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822064 | 0.84 | PIK3CA (0.80) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL13219299 | 0.77 | PRKDC (0.55) | PIK3CAPIK3CBPIK3CGPRKDCATM | |
| SCHEMBL1821760 | 0.74 | PIK3CA (0.84) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL2473407 | 0.73 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL13201846 | 0.72 | PIK3CA (0.87) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL2962548 | 0.72 | PRKDC (0.54) | PIK3CAPIK3CBPIK3CGPRKDCATM | |
| SCHEMBL1820931 | 0.72 | PIK3CA (0.70) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL12656244 | 0.71 | CYP1A2 (0.50) | PIK3CAPIK3CBPIK3CGPRKDCATM | |
| SCHEMBL2470746 | 0.71 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL1568863 | 0.70 | SRC (0.53) | PIK3CAPIK3CGPRKDCATMPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575940-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | claimed |